Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Cash (2019 - 2025)

Legend Biotech (LEGN) posted Change in Cash of $623.0 million for Q4 2025, up 3332.89% on a QoQ basis from $18.1 million in Q3 2025, and up 460.95% year-over-year from $111.1 million in Q4 2024.

Legend Biotech (LEGN) has 7 years of Change in Cash data on file, last reported at $623.0 million in Q4 2025.

  • In Q4 2025, Change in Cash rose 460.95% year-over-year to $623.0 million; the TTM figure through Dec 2025 stood at $615.1 million (up 162.07% YoY), while the FY2025 annual figure was $615.2 million, up 162.08% from the prior year.
  • Change in Cash grew to $623.0 million in Q4 2025, from $18.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $623.0 million in Q4 2025 and bottomed at -$696.3 million in Q2 2024.
  • A 5-year average of $22.4 million and a median of -$11.4 million in 2022 frame the typical range for Change in Cash.
  • Annual changes were most pronounced in 2022 — Change in Cash slumped 611.55% — and 2023, when it soared 19899.89%.
  • Year by year, Change in Cash stood at $350.5 million in 2021, then slumped by 107.3% to -$25.6 million in 2022, then surged by 1322.17% to $312.8 million in 2023, then sank by 155.18% to -$172.6 million in 2024, then jumped by 460.95% to $623.0 million in 2025.
  • The last three Change in Cash figures came in at $623.0 million (Q4 2025), $18.1 million (Q3 2025), and -$179.6 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 417.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -153.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.61 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - 57.19 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 623.00 Mn
Sep 30, 2025 18.15 Mn
Jun 30, 2025 -179.56 Mn
Mar 31, 2025 153.55 Mn
Dec 31, 2024 -172.60 Mn
Sep 30, 2024 257.69 Mn
Jun 30, 2024 -696.33 Mn
Mar 31, 2024 -379.80 Mn
Dec 31, 2023 312.79 Mn
Sep 30, 2023 -268.96 Mn
Jun 30, 2023 570.80 Mn
Mar 31, 2023 -123.63 Mn
Dec 31, 2022 -25.59 Mn
Sep 30, 2022 433.50 Mn
Jun 30, 2022 2.85 Mn
Mar 31, 2022 -311.16 Mn
Dec 31, 2021 350.53 Mn
Sep 30, 2021 -149.12 Mn
Jun 30, 2021 75.54 Mn
Mar 31, 2021 -43.73 Mn
Dec 31, 2020 5.87 Mn
Sep 30, 2020 -113.34 Mn
Jun 30, 2020 393.71 Mn
Mar 31, 2020 85.46 Mn
Dec 31, 2019 46.78 Mn
Sep 30, 2019 -1.40 Mn
Jun 30, 2019 -81.97 Mn